21:31:05 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-30 Kvartalsrapport 2024-Q2
2024-05-27 Ordinarie utdelning OBSRV 0.00 NOK
2024-05-24 Årsstämma 2024
2024-03-13 Bokslutskommuniké 2023
2023-11-22 Extra Bolagsstämma 2023
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-30 Ordinarie utdelning OBSRV 0.00 NOK
2023-05-26 Årsstämma 2023
2023-02-17 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-06-03 Årsstämma 2022
2022-06-03 Kvartalsrapport 2022-Q1
2022-06-03 Ordinarie utdelning OBSRV 0.00 NOK
2022-03-29 Bokslutskommuniké 2021
2022-02-04 Extra Bolagsstämma 2022
2021-11-03 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-25 Ordinarie utdelning OBSRV 0.00 NOK
2021-05-21 Årsstämma 2021
2021-05-12 Kvartalsrapport 2021-Q1
2021-02-23 Bokslutskommuniké 2020
2020-11-03 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning OBSRV 0.00 NOK
2020-06-30 Årsstämma 2020
2020-06-16 Extra Bolagsstämma 2020
2020-05-12 Kvartalsrapport 2020-Q1
2020-02-25 Bokslutskommuniké 2019

Beskrivning

LandNorge
ListaOAX Equities
SektorHälsovård
IndustriMedicinteknik
Observe Medical är ett norskt bolag verksamma inom medicinteknik. Bolaget bedriver utveckling av tekniska instrument som används inom intensivvården. Produkterna säljs under olika varumärken och är särskilt specialiserade för urinmätning. Störst verksamhet återfinns inom den nordiska samt europeiska marknaden. Bolaget kom till som en avknoppning från Navamedic och har sitt huvudkontor i Oslo, Norge.
2023-10-17 12:55:02
Oslo, October 17, 2023 - Observe Medical (OSE: OBSRV) Observe Medical ("the
Company" or "Observe Medical") today announces that it has delivered 20 Biim
ultrasound probes to Fresenius Medical Care in the US.

As part of the partnership agreement with Fresenius Medical Care, Observe
Medical has delivered 20 Biim ultrasound probes to Fresenius Medical Care, and
has at total now delivered 285 ultrasound probes to the leading provider of
kidney care services in the US.

For the last 1.5 years the main focus for the Company has been educational and
training support for approximately 265 educational dialysis clinics of
Fresenius. According to Fresenius this support has been necessary and needed to
optimize the use of the Biim technology amongst key personnel in Fresenius on a
daily basis. The intention is to secure that Fresenius is ready for a broader
implementation for use of the Biim ultrasound probe in all their approximately
2,700 dialysis clinics in the US.

"As earlier communicated, our relationship with Fresenius remains strong. Even
if no guarantees can be given for the timeline and scope of a broader
implementation, the order and delivery of 20 ultrasound probes confirms the
strong commitment Fresenius have to implement the ultrasound technology in their
dialysis clinics," said Rune Nystad.

For further information, please contact:

Rune Nystad, CEO Observe Medical
Mobile: +47 916 24 683
E-mail: rune.nystad@observemedical.com

Per Arne Nygård, CFO Observe Medical
Mobile: +47 411 04 345
E-mail: perarne.nygard@observemedical.com

About Fresenius Medical Care

Fresenius Medical Care offers products and services along the entire dialysis
value chain from a single source. They care for approximately 345,000 patients
in their global network of more than 4,000 dialysis clinics. At the same time,
they operate 42 production sites on all continents, to provide dialysis products
such as dialysis machines, dialyzers and related disposables.

Fresenius Medical Care aim to continuously improve the patients' quality of life
by offering them high-quality products as well as innovative technologies and
treatment concepts.

Fresenius Medical Care's corporate headquarters is in Bad Homburg v. d. Höhe,
Germany. The headquarters in North America is in Waltham, Massachusetts, the
headquarters of Asia-Pacific is located in Hong Kong and the headquarters of
Latin America is in Rio de Janeiro, Brazil.

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement, ultrasound, anesthesiology/ICUs, surgery and wound care,
in combination with targeted M&A.

The Company is headquartered in Oslo, Norway, with additional offices in Narvik,
Norway and Gothenburg, Sweden, and subsidiaries in Finland and the US. In
addition, Observe Medical has a direct sale organization in the Nordics and a
distributor network internationally.

Further information is available at www.observemedical.com.